Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

ACY-738

Copy Product Info
🥰Excellent
Catalog No. T3509Cas No. 1375465-91-0
Alias ACY 738

ACY-738 demonstrates inhibitory activity against recombinant HDAC6 (IC50: 1.7 nM), with respective average selectivity over class I HDACs being 100-fold.

ACY-738

ACY-738

Copy Product Info
🥰Excellent
Purity: 99.89%
Catalog No. T3509Alias ACY 738Cas No. 1375465-91-0
ACY-738 demonstrates inhibitory activity against recombinant HDAC6 (IC50: 1.7 nM), with respective average selectivity over class I HDACs being 100-fold.
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$41In StockIn Stock
2 mg$59In StockIn Stock
5 mg$97In StockIn Stock
10 mg$177In StockIn Stock
25 mg$297In StockIn Stock
50 mg$487In StockIn Stock
100 mg$647In StockIn Stock
1 mL x 10 mM (in DMSO)$107In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:99.89%
Color:White to Yellow
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
ACY-738 demonstrates inhibitory activity against recombinant HDAC6 (IC50: 1.7 nM), with respective average selectivity over class I HDACs being 100-fold.
Targets&IC50
HDAC6:1.7 nM, HDAC1:94 nM, HDAC3:218 nM, HDAC2:128 nM
In vitro
ACY-738 increases the acetylated (lysine 40) fraction of α-tubulin in RN46A-B14 cells at the concentration of 2.5?μM. The effect that ACY-738 (10 μM) induces cell death is similar to LBH589 and FK228.
In vivo
ACY-738 administered at a dosage of 5 mg/kg notably increases α-tubulin acetylation in whole-brain lysates, whereas a higher dosage (50 mg/kg) fails to enhance locomotor activity in wild-type (WT) mice within a home cage setting. At a dosage of 5 mg/kg by body weight (BW), ACY-738 influences B cell differentiation in bone marrow (BM) without significantly impacting immunoglobulin G (IgG) and complement component 3 (C3) deposition in NZB/W mice. This dosage also achieves a peak plasma concentration of 1310 ng/mL approximately 0.0830 hours post-treatment. When the dosage is increased to 20 mg/kg, ACY-738 markedly reduces the severity of proteinuria in NZB/W F1 mice and significantly lowers anti-double-stranded DNA (anti-dsDNA) production as well as glomerular interleukin-6 (IL-6) and interleukin-10 (IL-10) mRNA levels by more than 50% in NZB/W mice; the latter being reduced to non-detectable levels with the 20 mg/kg treatment. Additionally, both 5 and 20 mg/kg dosages of ACY-738 decrease serum interleukin-1 beta (IL-1β) production as the NZB/W mice age.
Kinase Assay
Recombinant kinase domain of EGFR L858R and T790M-L858R mutants are incubated with EGF816 to confirm covalent modification of EGFR and site of adduction. Recombinant enzyme is incubated at room temperature with a 20-fold molar excess of compound in 40 mM Tris, pH 8, 500 mM NaCl, 1% glycerol, 5 mM TCEP for 1 h. The reaction is quenched by addition of dithiothreitol (DTT, 80-fold excess to compound) and transfer to ice. A third of the reaction (10 μL) is processed for intact MS by adding an equal volume of 6 M Guan HCl, 100 mM Tris, pH 8, 20 mM DTT, 10 mM TCEP and incubating at room temperature for 15 min. Intact MS analysis is performed on an Agilent 6520 QToF mass spectrometer equipped with a dual spray ion source (IS of 4500 V, fragmentor of 250 V, fas temp of 350°C, and skimmer of 75 V). The samples are injected onto a PLRP-S column (2.1 mm × 50 mm), heated to 60°C, and desalted for 2 min at 500 μL/min and 3% B prior to elution with a fast gradient of 3-50% B in 3 min (B, 0.1% formic acid). The data are analyzed in MassHunter for automatic peak selection, integration, and spectral deconvolution with a mass range of 15?000-75?000 Da.
SynonymsACY 738
Chemical Properties
Molecular Weight270.29
FormulaC14H14N4O2
Cas No.1375465-91-0
SmilesN(C1(CC1)C2=CC=CC=C2)C=3N=CC(C(NO)=O)=CN3
Relative Density.1.433 g/cm3 (Predicted)
Storage & Solubility Information
StorageIn solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 50 mg/mL (184.99 mM), Sonication is recommended.
In Vivo Formulation
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (7.4 mM), Sonication is recommended.
Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM3.6997 mL18.4986 mL36.9973 mL184.9865 mL
5 mM0.7399 mL3.6997 mL7.3995 mL36.9973 mL
10 mM0.3700 mL1.8499 mL3.6997 mL18.4986 mL
20 mM0.1850 mL0.9249 mL1.8499 mL9.2493 mL
50 mM0.0740 mL0.3700 mL0.7399 mL3.6997 mL
100 mM0.0370 mL0.1850 mL0.3700 mL1.8499 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy ACY-738 | purchase ACY-738 | ACY-738 cost | order ACY-738 | ACY-738 chemical structure | ACY-738 in vivo | ACY-738 in vitro | ACY-738 formula | ACY-738 molecular weight